FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091356458> ?p ?o ?g. }

• W2091356458 endingPage "211" @default.
• W2091356458 startingPage "204" @default.
• W2091356458 abstract "Abstract Objectives/Hypothesis: To evaluate the hearing changes and quality‐of‐life outcomes of 393 cases of streptomycin/dexamethasone inner ear perfusion performed by the primary author on 312 ears of 299 patients with Meniere's disease between July 2002 and May 2010. Study Design: Retrospective chart review. Methods: Objective arm: A database was used to compile pretreatment and post‐treatment audiograms as well as basic demographic information, dates of treatment, number of treatments, and which ear was treated. All patients met the 1995 American Academy of Otolaryngology–Head and Neck Surgery Committee on Hearing and Equilibrium Guidelines for the diagnosis and evaluation of therapy in Meniere's disease. All patients underwent one or more 3‐day treatments consisting of daily intratympanic injections of a low‐dose streptomycin/high‐dose dexamethasone mixture plus intravenous dexamethasone. The end point for treatment was adequate control of vertigo. Subjective arm: The Meniere's Disease Outcomes Questionnaire survey was used to assess patients' quality of life after receiving streptomycin/dexamethasone inner ear perfusion. All procedures were performed by the primary author at the Shea Ear Clinic, a tertiary‐referral otology clinic and outpatient surgery center. Results: After a single 3‐day treatment, the average change in pure tone average was 0.89 dB (±11). The average change in word recognition score was 0.49% (±17). The average number of days from treatment to follow‐up audiogram was 94 with a range of 8 to 1,603. Clinically significant hearing loss occurred after 62 of 393 (15.7%) treatments. Severe hearing loss occurred after 20 of 393 treatments (5.0%). The percentage of ears with clinically significant hearing loss after all treatments was 56 of 312 (17.9%). A total of 215 surveys were returned from 383 patients (56.1%) to whom they were mailed. There were 90% of patients who indicated improvement in quality of life after treatment and 88% who indicated improvement in their “vertigo subscore,” a domain within the survey that focuses on vertigo control. Conclusions: Streptomycin/dexamethasone inner ear perfusion is as safe to the hearing of patients with Meniere's disease as other aminoglycoside regimens and provides a significant improvement in quality of life.Laryngoscope, 122:204–211, 2012" @default.
• W2091356458 created "2016-06-24" @default.
• W2091356458 creator A5038947913 @default.
• W2091356458 creator A5053956736 @default.
• W2091356458 creator A5070860121 @default.
• W2091356458 creator A5076984214 @default.
• W2091356458 date "2011-12-19" @default.
• W2091356458 modified "2023-10-10" @default.
• W2091356458 title "Hearing results and quality of life after streptomycin/dexamethasone perfusion for meniere's disease" @default.
• W2091356458 cites W1931996274 @default.
• W2091356458 cites W1970513271 @default.
• W2091356458 cites W1971973958 @default.
• W2091356458 cites W1986752216 @default.
• W2091356458 cites W1996859283 @default.
• W2091356458 cites W1999335971 @default.
• W2091356458 cites W1999852526 @default.
• W2091356458 cites W2002875893 @default.
• W2091356458 cites W2017677968 @default.
• W2091356458 cites W2018241677 @default.
• W2091356458 cites W2021277173 @default.
• W2091356458 cites W2022438449 @default.
• W2091356458 cites W2026679424 @default.
• W2091356458 cites W2029438761 @default.
• W2091356458 cites W2030624857 @default.
• W2091356458 cites W2034861025 @default.
• W2091356458 cites W2037502667 @default.
• W2091356458 cites W2040319990 @default.
• W2091356458 cites W2077582465 @default.
• W2091356458 cites W2081453354 @default.
• W2091356458 cites W2093779566 @default.
• W2091356458 cites W2098670479 @default.
• W2091356458 cites W2104208073 @default.
• W2091356458 cites W2110001084 @default.
• W2091356458 cites W2128941263 @default.
• W2091356458 cites W2256410958 @default.
• W2091356458 cites W2319545333 @default.
• W2091356458 cites W2407520631 @default.
• W2091356458 cites W2409792338 @default.
• W2091356458 cites W31832217 @default.
• W2091356458 cites W4300666453 @default.
• W2091356458 cites W4312707569 @default.
• W2091356458 cites W54595123 @default.
• W2091356458 cites W89150063 @default.
• W2091356458 cites W2048882933 @default.
• W2091356458 doi "https://doi.org/10.1002/lary.22362" @default.
• W2091356458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22183636" @default.
• W2091356458 hasPublicationYear "2011" @default.
• W2091356458 type Work @default.
• W2091356458 sameAs 2091356458 @default.
• W2091356458 citedByCount "22" @default.
• W2091356458 countsByYear W20913564582012 @default.
• W2091356458 countsByYear W20913564582013 @default.
• W2091356458 countsByYear W20913564582014 @default.
• W2091356458 countsByYear W20913564582015 @default.
• W2091356458 countsByYear W20913564582016 @default.
• W2091356458 countsByYear W20913564582017 @default.
• W2091356458 countsByYear W20913564582018 @default.
• W2091356458 countsByYear W20913564582019 @default.
• W2091356458 countsByYear W20913564582021 @default.
• W2091356458 countsByYear W20913564582023 @default.
• W2091356458 crossrefType "journal-article" @default.
• W2091356458 hasAuthorship W2091356458A5038947913 @default.
• W2091356458 hasAuthorship W2091356458A5053956736 @default.
• W2091356458 hasAuthorship W2091356458A5070860121 @default.
• W2091356458 hasAuthorship W2091356458A5076984214 @default.
• W2091356458 hasConcept C108516343 @default.
• W2091356458 hasConcept C126322002 @default.
• W2091356458 hasConcept C141071460 @default.
• W2091356458 hasConcept C17743292 @default.
• W2091356458 hasConcept C2776992516 @default.
• W2091356458 hasConcept C2779135839 @default.
• W2091356458 hasConcept C2780401358 @default.
• W2091356458 hasConcept C2780493683 @default.
• W2091356458 hasConcept C2780554537 @default.
• W2091356458 hasConcept C2780835470 @default.
• W2091356458 hasConcept C2780865074 @default.
• W2091356458 hasConcept C3017913842 @default.
• W2091356458 hasConcept C540533750 @default.
• W2091356458 hasConcept C548259974 @default.
• W2091356458 hasConcept C71924100 @default.
• W2091356458 hasConceptScore W2091356458C108516343 @default.
• W2091356458 hasConceptScore W2091356458C126322002 @default.
• W2091356458 hasConceptScore W2091356458C141071460 @default.
• W2091356458 hasConceptScore W2091356458C17743292 @default.
• W2091356458 hasConceptScore W2091356458C2776992516 @default.
• W2091356458 hasConceptScore W2091356458C2779135839 @default.
• W2091356458 hasConceptScore W2091356458C2780401358 @default.
• W2091356458 hasConceptScore W2091356458C2780493683 @default.
• W2091356458 hasConceptScore W2091356458C2780554537 @default.
• W2091356458 hasConceptScore W2091356458C2780835470 @default.
• W2091356458 hasConceptScore W2091356458C2780865074 @default.
• W2091356458 hasConceptScore W2091356458C3017913842 @default.
• W2091356458 hasConceptScore W2091356458C540533750 @default.
• W2091356458 hasConceptScore W2091356458C548259974 @default.
• W2091356458 hasConceptScore W2091356458C71924100 @default.
• W2091356458 hasIssue "1" @default.
• W2091356458 hasLocation W20913564581 @default.
• W2091356458 hasLocation W20913564582 @default.

• next